264P - Is there any difference in clinicopathological factors and prognosis of the young breast cancer?

Date 01 October 2012
Event ESMO Congress 2012
Session Poster presentation III
Topics Pathology/Molecular Biology
Breast Cancer
Cancers in Adolescents and Young Adults (AYA)
Basic Scientific Principles
Presenter Yuka Kajiura
Authors Y. Kajiura1, Y. Ishida2, H. Yagata3, N. Hayashi3, A. Yoshida4, H. Yamauchi5
  • 1St Luke's International Hospital, 104-8560 - Tokyo/JP
  • 2Center For Clinical Epidemiology, St.Luke's Life Science Institute, 104-0044 - Tokyo/JP
  • 3Breast Surgical Oncology, St Luke's International Hospital, 104-8560 - Tokyo/JP
  • 4Breast Surgical Oncology, St. Luke's International Hospital, 104-8560 - Tokyo/JP
  • 5Breast Surgical Oncology, St. Luke's International Hospital, JP-104-8560 - Tokyo/JP



Young breast cancer patients have been increasing in Japan over the last several decades and have been reported to have poorer prognosis than older women. However, differences in prognosis for young patients remain uncertain. The objective of this study is to compare clinicopathological factors and prognosis between breast cancer patients under 35 years versus those 35-39 years of age.

Patients and methods

Sixty hundred eighty four women under 40 years were diagnosed breast cancer in our hospital from 1994 to 2008. Patients with bilateral breast cancer, without surgical treatment in our hospital, those with incomplete clinical data, and patients who received neoadjuvant chemotherapy were excluded from further analysis. The remaining 400 women were enrolled in this study. We first assessed clinicopathological factors associated with prognosis in all enrolled patients. Clinicopathological factors included family history of breast cancer, palpated tumor size and lymph nodes, pathological findings (histological type, tumor size, lymph node metastasis, nuclear grade, vessel invasion, lymphatic invasion, and ER, PgR, HER2 status), surgical procedure (mastectomy or breast conserving surgery), postoperative radiation therapy and adjuvant therapy. Next, we compared clinicopathological factors, disease-free survival (DFS) and overall survival (OS) between patients under 35 years versus those 35-39 years of age.


Of the 400 patients, 139 (34.8%) were under 35 years old and 261 (65.2%) were 35-39 years old with a median follow-up of 72.5 months (range,1-211months). Postoperative radiation therapy was associated with longer DFS (HR, 0.130; p = 0.007) and OS (HR, 0.017; p = 0.001) in multivariate analysis of the 400 patients. However, there were no significant differences in clinicopathological factors, DFS and OS between under 35 years and those 35-39 years of age.


Our results suggested that postoperative radiation therapy improved the prognosis in young breast cancer patients. However, age at diagnosis was not associated with DFS or OS in patients under 40 years. Therefore, we recommend patients under 40 years to receive unified therapy.


All authors have declared no conflicts of interest.